Bioretec, a Finland-based company, is set to broaden its market reach in the United States through a new sales and distribution agreement with Tri-State Biologics (TSB). This collaboration aims to facilitate the distribution of Bioretec's RemeOs bioresorbable implants to hospitals across Greater New York City, Philadelphia, New Jersey, Connecticut, and Massachusetts.
The agreement with TSB, a New Jersey-based distributor of medical and surgical products with 18 sales representatives, builds upon a previous logistics agreement with GlobalMed Logistix. Alan Donze, CEO of Bioretec, expressed enthusiasm for the partnership, highlighting TSB's innovative approach to medical product distribution.
The expansion follows a controlled initial launch of RemeOs trauma screws in the U.S., which yielded promising patient results, including successful surgeries and positive post-healing follow-ups. This initial success has paved the way for the second phase of commercialization of RemeOs products in the U.S., with a focus on driving demand within the surgeon community.
Bioretec plans to establish additional local sales and distribution agreements to serve civilian hospitals throughout the U.S., while its partner, Spartan Medical, will continue to cater to military and veteran hospitals. The company's strategic move to increase production capacity, including the acquisition of a new CNC machining center optimized for magnesium-based implants like RemeOs, underscores its commitment to meeting the growing demand for its products.
RemeOs implants are designed to be resorbed by the body and replaced by bone, eliminating the need for a second surgery to remove the implant. This feature promotes natural healing and reduces patient burden. The RemeOs screw received FDA approval in March, marking a significant milestone for Bioretec.
